Q1 Rundown: Amplitude (NASDAQ:AMPL) Vs Other Data Analytics Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s have a look at how the data analytics stocks have fared in Q1, starting with Amplitude (NASDAQ:AMPL).

Organizations generate a lot of data that is stored in silos, often in incompatible formats, making it slow and costly to extract actionable insights, which in turn drives demand for modern cloud-based data analysis platforms that can efficiently analyze the silo-ed data.

The 5 data analytics stocks we track reported a weaker Q1; on average, revenues beat analyst consensus estimates by 1.92%, while on average next quarter revenue guidance was 3.4% under consensus. Investors abandoned cash burning companies since high interest rates will make it harder to raise capital, but data analytics stocks held their ground better than others, with the share prices up 9.44% since the previous earnings results, on average.

Amplitude (NASDAQ:AMPL)

Born out of a failed voice recognition startup by founder Spenser Skates, Amplitude (NASDAQ:AMPL) is data analytics software helping companies improve and optimize their digital products.

Amplitude reported revenues of $66.5 million, up 25.3% year on year, beating analyst expectations by 1.9%. It was a weaker quarter for the company, with revenue guidance for the next quarter and the full year missing analysts' expectations.

"Every business with a digital product needs digital analytics," said Spenser Skates, CEO and co-founder of Amplitude.

Amplitude delivered the weakest full year guidance update of the whole group. The company added 181 customers to a total of 2,175. The stock is down 9.47% since the results and currently trades at $10.52.

Read our full report on Amplitude here, it's free.

Best Q1: Health Catalyst (NASDAQ:HCAT)

Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.

Health Catalyst reported revenues of $73.9 million, up 8.49% year on year, beating analyst expectations by 3.66%. It was a mixed quarter for the company, with a decent beat of topline estimates. However, revenue guidance for the next quarter and full year slightly missed analysts' expectations.

The stock is down 5.61% since the results and currently trades at $11.27.

Is now the time to buy Health Catalyst? Access our full analysis of the earnings results here, it's free.

Weakest Q1: Alteryx (NYSE:AYX)

Initially created as a way to organise census data for the government, Alteryx (NYSE:AYX) provides software that helps companies automate and analyse their internal data processes.

Alteryx reported revenues of $199.1 million, up 26.1% year on year, missing analyst expectations by 0.49%. It was a weak quarter for the company, with underwhelming revenue guidance for the next quarter and decelerating customer growth.

Alteryx scored the fastest revenue growth but had the weakest performance against analyst estimates in the group. The company lost 20 customers and ended up with a total of 8,338. The stock is down 16.6% since the results and currently trades at $42.53.

Read our full analysis of Alteryx's results here.

Palantir (NYSE:PLTR)

Started by Peter Thiel after seeing US defence agencies struggle in the aftermath of the 2001 terrorist attacks, Palantir (NYSE:PLTR) offers software as a service platform that helps government agencies and large enterprises use data to make better decisions.

Palantir reported revenues of $525.2 million, up 17.7% year on year, beating analyst expectations by 3.8%. It was a slower quarter for the company, with underwhelming revenue guidance for the next quarter. Despite this, management noted that the company is expected to remain profitable every quarter through the end of the year.

Palantir scored the strongest analyst estimates beat and highest full year guidance raise among the peers. The stock is up 82.5% since the results and currently trades at $14.16.

Read our full, actionable report on Palantir here, it's free.

Domo (NASDAQ:DOMO)

Founded by Josh James after selling his former business Omniture to Adobe, Domo (NASDAQ:DOMO) provides business intelligence software that allows managers to access and visualize critical business metrics in real-time, using their smartphones.

Domo reported revenues of $79.5 million, up 6.71% year on year, in line with analyst expectations. It was a weaker quarter for the company, with underwhelming revenue guidance for the next quarter.

Domo had the slowest revenue growth among the peers. The stock is down 3.58% since the results and currently trades at $14.28.

Read our full, actionable report on Domo here, it's free.

The author has no position in any of the stocks mentioned